After taking a $245 million hit from the levies in 2025, CFO James Saccaro said the company plans more actions to mitigate ...
The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果